[摘 要] 过继细胞疗法在肿瘤免疫治疗领域持续革新，其中双特异性抗体武装T细胞/自然杀伤细胞（T/NK细胞）技术通过抗 体靶向并桥接免疫细胞，赋予其精准靶向杀伤能力的同时突破传统技术局限，兼具制备标准化程度高、安全性可控及临床转化周 期短等核心优势，在实体瘤及血液系统恶性肿瘤治疗中均呈现出突破性临床潜力。本文系统评述嵌合抗原受体基因修饰T淋巴 细胞/自然杀伤细胞（CAR-T/NK细胞）、肿瘤浸润淋巴细胞（TIL）和细胞因子诱导的记忆样NK细胞（CIML NK细胞）疗法的研究 进展，并重点探讨双特异性抗体武装T/NK细胞技术的作用机制、优势、临床进展及前沿趋势。

[Abstract] Adoptive cell therapy continues to drive innovation in cancer immunotherapy. Among the emerging approaches, bispecific antibody (BsAb)-armed T cell and NK cell (T/NK cell) technology leverages antibodies to specifically target tumor antigens and bridge immune effector cells, thereby endowing these cells with precise tumor-killing capabilities while overcoming the limitations of traditional therapeutic strategies. This technology is characterized by its high degree of standardization, controllable safety, and a short clinical translational cycle, demonstrating promising therapeutic potential in both solid tumors and hematologic malignancies. This article provides a comprehensive review of the advancements in chimeric antigen receptor-engineered T/NK cell (CAR-T/NK cell), tumor-infiltrating lymphocyte (TIL), and cytokine-induced memory-like NK cell (CIML NK) therapies. Particular emphasis is placed on the mechanisms of action, advantages, clinical progress, and emerging trends of BsAb-armed T/NK cell therapy.

[基金项目] “十四五”江苏省医学重点学科（No. ZDXK202233）； 南京市肿瘤医学重点实验室项目；国家中西医协同“旗舰”科室 项目